Notwithstanding promising clinical data, copyright's Vyndamax, check here a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial difficulty from managed care entities. The companies are frequently creating obstacles to reimbursement, such as significant expense requirements and PA that restrict patient access. An